The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children
Long term follow-up of vaccine trials is essential to establish the duration of protection. In the context of worldwide concern about rising pertussis incidence, estimates of antibody persistence after vaccination, which do not account for the rise in antibody due to natural boosting or infection, m...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2016-07, Vol.34 (35), p.4221-4228 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4228 |
|---|---|
| container_issue | 35 |
| container_start_page | 4221 |
| container_title | Vaccine |
| container_volume | 34 |
| creator | Voysey, Merryn Kandasamy, Rama Yu, Ly-Mee Baudin, Martine Sadorge, Christine Thomas, Stéphane John, Tessa Pollard, Andrew J. |
| description | Long term follow-up of vaccine trials is essential to establish the duration of protection. In the context of worldwide concern about rising pertussis incidence, estimates of antibody persistence after vaccination, which do not account for the rise in antibody due to natural boosting or infection, may overestimate the degree of protection afforded by pertussis vaccines.
This was a 5year follow up study of a randomised controlled trial of diphtheria, tetanus, pertussis and polio booster vaccines in UK children aged 3.5–5years. Antibody persistence was measured at 1month, 1, 3, and 5years after vaccination and the kinetics of antibody decline were modelled longitudinally. Estimates of predicted antibody persistence 9years after the pre-school booster were derived from model parameters.
Antibody levels 9years after vaccination were predicted to be above accepted thresholds for protection for diphtheria, tetanus and polio. Antibody responses to pertussis toxoid were undetectable in 49% of children at the 5year follow up visit, and responses were predicted to be undetectable in 69% (95% CI 45–88%) of children by the time of their teenage booster at 13–14years of age.
There is no defined correlate of protection for pertussis. However, the large proportion of participants in this study with undetectable pertussis antibody levels at both measured and predicted timepoints suggests sub-optimal immunity in adolescence. Adding pertussis to the teenage booster for UK children as is done in other countries, would enhance immunity in adolescence. |
| doi_str_mv | 10.1016/j.vaccine.2016.06.051 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1808640251</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X16304753</els_id><sourcerecordid>1808640251</sourcerecordid><originalsourceid>FETCH-LOGICAL-e1736-fab954cf68832584fc0c9d49b460ffb80be84b8deb224dde674b1c33aa9d8bd13</originalsourceid><addsrcrecordid>eNqNkU9rGzEQxUVJaRy3H6FFkEsu60grrSydSjBpUxLoJYHchP7MYm3XK1faNfjbR4vdS06FATHDj9Gb9xD6SsmKEipuu9XBOBcGWNWlXZFSDf2AFlSuWVU3VF6gBakFrzglr5foKueOENIwqj6hy3rNBCdKLND0vAW8T-CDG8HjPaQc8giDA2wGj_-UD8bgMo5t6cdgoz9iD64vc6yOYFLGph0hzTuq7LYx9tjGmOfRSaAZQxxwGPDLI3bb0PsEw2f0sTV9hi_nd4leftw_bx6qp98_f23uniqgRWHVGqsa7lohJasbyVtHnPJcWS5I21pJLEhupQdb19x7EGtuqWPMGOWl9ZQt0c1p7z7FvxPkUe9CdtD3ZoA4ZU0lkcWIYtf_oIKzNWWyoNfv0C5OaSiHzFTDRa2YKtS3MzXZHXi9T2Fn0lH_874A308AFAcOAZLOLszO-5DAjdrHoCnRc9q60-e09Zy2JqWK5jflWZ7B</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1805462939</pqid></control><display><type>article</type><title>The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>ProQuest Central UK/Ireland</source><creator>Voysey, Merryn ; Kandasamy, Rama ; Yu, Ly-Mee ; Baudin, Martine ; Sadorge, Christine ; Thomas, Stéphane ; John, Tessa ; Pollard, Andrew J.</creator><creatorcontrib>Voysey, Merryn ; Kandasamy, Rama ; Yu, Ly-Mee ; Baudin, Martine ; Sadorge, Christine ; Thomas, Stéphane ; John, Tessa ; Pollard, Andrew J.</creatorcontrib><description>Long term follow-up of vaccine trials is essential to establish the duration of protection. In the context of worldwide concern about rising pertussis incidence, estimates of antibody persistence after vaccination, which do not account for the rise in antibody due to natural boosting or infection, may overestimate the degree of protection afforded by pertussis vaccines.
This was a 5year follow up study of a randomised controlled trial of diphtheria, tetanus, pertussis and polio booster vaccines in UK children aged 3.5–5years. Antibody persistence was measured at 1month, 1, 3, and 5years after vaccination and the kinetics of antibody decline were modelled longitudinally. Estimates of predicted antibody persistence 9years after the pre-school booster were derived from model parameters.
Antibody levels 9years after vaccination were predicted to be above accepted thresholds for protection for diphtheria, tetanus and polio. Antibody responses to pertussis toxoid were undetectable in 49% of children at the 5year follow up visit, and responses were predicted to be undetectable in 69% (95% CI 45–88%) of children by the time of their teenage booster at 13–14years of age.
There is no defined correlate of protection for pertussis. However, the large proportion of participants in this study with undetectable pertussis antibody levels at both measured and predicted timepoints suggests sub-optimal immunity in adolescence. Adding pertussis to the teenage booster for UK children as is done in other countries, would enhance immunity in adolescence.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2016.06.051</identifier><identifier>PMID: 27364096</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Adolescent ; Adolescents ; Age ; Antibodies, Bacterial - blood ; Antibodies, Viral - blood ; Antibody Formation ; Antigens ; Child ; Child, Preschool ; Children ; Confidence intervals ; Diphtheria ; Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage ; Diphtheria-Tetanus-acellular Pertussis Vaccines - therapeutic use ; Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage ; Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use ; Female ; Follow-Up Studies ; Humans ; Immunization, Secondary ; Immunogenicity ; Immunoglobulins ; Infections ; Kinetics ; Laboratories ; Male ; Methods ; Persistence ; Pertussis ; Polio ; Poliomyelitis ; Poliovirus Vaccine, Inactivated - administration & dosage ; Poliovirus Vaccine, Inactivated - therapeutic use ; Poliovirus Vaccine, Oral - administration & dosage ; Poliovirus Vaccine, Oral - therapeutic use ; Public health ; Tetanus ; Toxoids - immunology ; United Kingdom ; Vaccines ; Vaccines, Combined - administration & dosage ; Vaccines, Combined - therapeutic use ; Whooping cough</subject><ispartof>Vaccine, 2016-07, Vol.34 (35), p.4221-4228</ispartof><rights>2016 Elsevier Ltd</rights><rights>Copyright © 2016 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jul 29, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1805462939?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,45974,64362,64364,64366,72216</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27364096$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Voysey, Merryn</creatorcontrib><creatorcontrib>Kandasamy, Rama</creatorcontrib><creatorcontrib>Yu, Ly-Mee</creatorcontrib><creatorcontrib>Baudin, Martine</creatorcontrib><creatorcontrib>Sadorge, Christine</creatorcontrib><creatorcontrib>Thomas, Stéphane</creatorcontrib><creatorcontrib>John, Tessa</creatorcontrib><creatorcontrib>Pollard, Andrew J.</creatorcontrib><title>The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Long term follow-up of vaccine trials is essential to establish the duration of protection. In the context of worldwide concern about rising pertussis incidence, estimates of antibody persistence after vaccination, which do not account for the rise in antibody due to natural boosting or infection, may overestimate the degree of protection afforded by pertussis vaccines.
This was a 5year follow up study of a randomised controlled trial of diphtheria, tetanus, pertussis and polio booster vaccines in UK children aged 3.5–5years. Antibody persistence was measured at 1month, 1, 3, and 5years after vaccination and the kinetics of antibody decline were modelled longitudinally. Estimates of predicted antibody persistence 9years after the pre-school booster were derived from model parameters.
Antibody levels 9years after vaccination were predicted to be above accepted thresholds for protection for diphtheria, tetanus and polio. Antibody responses to pertussis toxoid were undetectable in 49% of children at the 5year follow up visit, and responses were predicted to be undetectable in 69% (95% CI 45–88%) of children by the time of their teenage booster at 13–14years of age.
There is no defined correlate of protection for pertussis. However, the large proportion of participants in this study with undetectable pertussis antibody levels at both measured and predicted timepoints suggests sub-optimal immunity in adolescence. Adding pertussis to the teenage booster for UK children as is done in other countries, would enhance immunity in adolescence.</description><subject>Adolescent</subject><subject>Adolescents</subject><subject>Age</subject><subject>Antibodies, Bacterial - blood</subject><subject>Antibodies, Viral - blood</subject><subject>Antibody Formation</subject><subject>Antigens</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Confidence intervals</subject><subject>Diphtheria</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage</subject><subject>Diphtheria-Tetanus-acellular Pertussis Vaccines - therapeutic use</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage</subject><subject>Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunization, Secondary</subject><subject>Immunogenicity</subject><subject>Immunoglobulins</subject><subject>Infections</subject><subject>Kinetics</subject><subject>Laboratories</subject><subject>Male</subject><subject>Methods</subject><subject>Persistence</subject><subject>Pertussis</subject><subject>Polio</subject><subject>Poliomyelitis</subject><subject>Poliovirus Vaccine, Inactivated - administration & dosage</subject><subject>Poliovirus Vaccine, Inactivated - therapeutic use</subject><subject>Poliovirus Vaccine, Oral - administration & dosage</subject><subject>Poliovirus Vaccine, Oral - therapeutic use</subject><subject>Public health</subject><subject>Tetanus</subject><subject>Toxoids - immunology</subject><subject>United Kingdom</subject><subject>Vaccines</subject><subject>Vaccines, Combined - administration & dosage</subject><subject>Vaccines, Combined - therapeutic use</subject><subject>Whooping cough</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkU9rGzEQxUVJaRy3H6FFkEsu60grrSydSjBpUxLoJYHchP7MYm3XK1faNfjbR4vdS06FATHDj9Gb9xD6SsmKEipuu9XBOBcGWNWlXZFSDf2AFlSuWVU3VF6gBakFrzglr5foKueOENIwqj6hy3rNBCdKLND0vAW8T-CDG8HjPaQc8giDA2wGj_-UD8bgMo5t6cdgoz9iD64vc6yOYFLGph0hzTuq7LYx9tjGmOfRSaAZQxxwGPDLI3bb0PsEw2f0sTV9hi_nd4leftw_bx6qp98_f23uniqgRWHVGqsa7lohJasbyVtHnPJcWS5I21pJLEhupQdb19x7EGtuqWPMGOWl9ZQt0c1p7z7FvxPkUe9CdtD3ZoA4ZU0lkcWIYtf_oIKzNWWyoNfv0C5OaSiHzFTDRa2YKtS3MzXZHXi9T2Fn0lH_874A308AFAcOAZLOLszO-5DAjdrHoCnRc9q60-e09Zy2JqWK5jflWZ7B</recordid><startdate>20160729</startdate><enddate>20160729</enddate><creator>Voysey, Merryn</creator><creator>Kandasamy, Rama</creator><creator>Yu, Ly-Mee</creator><creator>Baudin, Martine</creator><creator>Sadorge, Christine</creator><creator>Thomas, Stéphane</creator><creator>John, Tessa</creator><creator>Pollard, Andrew J.</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7U2</scope></search><sort><creationdate>20160729</creationdate><title>The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children</title><author>Voysey, Merryn ; Kandasamy, Rama ; Yu, Ly-Mee ; Baudin, Martine ; Sadorge, Christine ; Thomas, Stéphane ; John, Tessa ; Pollard, Andrew J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e1736-fab954cf68832584fc0c9d49b460ffb80be84b8deb224dde674b1c33aa9d8bd13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adolescent</topic><topic>Adolescents</topic><topic>Age</topic><topic>Antibodies, Bacterial - blood</topic><topic>Antibodies, Viral - blood</topic><topic>Antibody Formation</topic><topic>Antigens</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Confidence intervals</topic><topic>Diphtheria</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage</topic><topic>Diphtheria-Tetanus-acellular Pertussis Vaccines - therapeutic use</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage</topic><topic>Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunization, Secondary</topic><topic>Immunogenicity</topic><topic>Immunoglobulins</topic><topic>Infections</topic><topic>Kinetics</topic><topic>Laboratories</topic><topic>Male</topic><topic>Methods</topic><topic>Persistence</topic><topic>Pertussis</topic><topic>Polio</topic><topic>Poliomyelitis</topic><topic>Poliovirus Vaccine, Inactivated - administration & dosage</topic><topic>Poliovirus Vaccine, Inactivated - therapeutic use</topic><topic>Poliovirus Vaccine, Oral - administration & dosage</topic><topic>Poliovirus Vaccine, Oral - therapeutic use</topic><topic>Public health</topic><topic>Tetanus</topic><topic>Toxoids - immunology</topic><topic>United Kingdom</topic><topic>Vaccines</topic><topic>Vaccines, Combined - administration & dosage</topic><topic>Vaccines, Combined - therapeutic use</topic><topic>Whooping cough</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Voysey, Merryn</creatorcontrib><creatorcontrib>Kandasamy, Rama</creatorcontrib><creatorcontrib>Yu, Ly-Mee</creatorcontrib><creatorcontrib>Baudin, Martine</creatorcontrib><creatorcontrib>Sadorge, Christine</creatorcontrib><creatorcontrib>Thomas, Stéphane</creatorcontrib><creatorcontrib>John, Tessa</creatorcontrib><creatorcontrib>Pollard, Andrew J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>Safety Science and Risk</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Voysey, Merryn</au><au>Kandasamy, Rama</au><au>Yu, Ly-Mee</au><au>Baudin, Martine</au><au>Sadorge, Christine</au><au>Thomas, Stéphane</au><au>John, Tessa</au><au>Pollard, Andrew J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2016-07-29</date><risdate>2016</risdate><volume>34</volume><issue>35</issue><spage>4221</spage><epage>4228</epage><pages>4221-4228</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Long term follow-up of vaccine trials is essential to establish the duration of protection. In the context of worldwide concern about rising pertussis incidence, estimates of antibody persistence after vaccination, which do not account for the rise in antibody due to natural boosting or infection, may overestimate the degree of protection afforded by pertussis vaccines.
This was a 5year follow up study of a randomised controlled trial of diphtheria, tetanus, pertussis and polio booster vaccines in UK children aged 3.5–5years. Antibody persistence was measured at 1month, 1, 3, and 5years after vaccination and the kinetics of antibody decline were modelled longitudinally. Estimates of predicted antibody persistence 9years after the pre-school booster were derived from model parameters.
Antibody levels 9years after vaccination were predicted to be above accepted thresholds for protection for diphtheria, tetanus and polio. Antibody responses to pertussis toxoid were undetectable in 49% of children at the 5year follow up visit, and responses were predicted to be undetectable in 69% (95% CI 45–88%) of children by the time of their teenage booster at 13–14years of age.
There is no defined correlate of protection for pertussis. However, the large proportion of participants in this study with undetectable pertussis antibody levels at both measured and predicted timepoints suggests sub-optimal immunity in adolescence. Adding pertussis to the teenage booster for UK children as is done in other countries, would enhance immunity in adolescence.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>27364096</pmid><doi>10.1016/j.vaccine.2016.06.051</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2016-07, Vol.34 (35), p.4221-4228 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1808640251 |
| source | MEDLINE; Elsevier ScienceDirect Journals; ProQuest Central UK/Ireland |
| subjects | Adolescent Adolescents Age Antibodies, Bacterial - blood Antibodies, Viral - blood Antibody Formation Antigens Child Child, Preschool Children Confidence intervals Diphtheria Diphtheria-Tetanus-acellular Pertussis Vaccines - administration & dosage Diphtheria-Tetanus-acellular Pertussis Vaccines - therapeutic use Diphtheria-Tetanus-Pertussis Vaccine - administration & dosage Diphtheria-Tetanus-Pertussis Vaccine - therapeutic use Female Follow-Up Studies Humans Immunization, Secondary Immunogenicity Immunoglobulins Infections Kinetics Laboratories Male Methods Persistence Pertussis Polio Poliomyelitis Poliovirus Vaccine, Inactivated - administration & dosage Poliovirus Vaccine, Inactivated - therapeutic use Poliovirus Vaccine, Oral - administration & dosage Poliovirus Vaccine, Oral - therapeutic use Public health Tetanus Toxoids - immunology United Kingdom Vaccines Vaccines, Combined - administration & dosage Vaccines, Combined - therapeutic use Whooping cough |
| title | The predicted persistence and kinetics of antibody decline 9years after pre-school booster vaccination in UK children |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T06%3A30%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20predicted%20persistence%20and%20kinetics%20of%20antibody%20decline%209years%20after%20pre-school%20booster%20vaccination%20in%20UK%20children&rft.jtitle=Vaccine&rft.au=Voysey,%20Merryn&rft.date=2016-07-29&rft.volume=34&rft.issue=35&rft.spage=4221&rft.epage=4228&rft.pages=4221-4228&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2016.06.051&rft_dat=%3Cproquest_pubme%3E1808640251%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1805462939&rft_id=info:pmid/27364096&rft_els_id=S0264410X16304753&rfr_iscdi=true |